When this site covers a new trial result, one detail is easy to skip past but genuinely changes how much weight the result deserves: whether the trial was blinded or open-label. Both are legitimate research designs, but they carry different strengths and different risks of bias, and recent head-to-head peptide-drug trials have leaned heavily on the open-label format.
The Basic Difference
In a blinded (or masked) trial, participants don't know which treatment they're receiving, and often the researchers assessing outcomes don't know either (a "double-blind" design). This is usually accomplished by giving everyone an identical-looking placebo or comparator so no one can tell the assignments apart just by looking. In an open-label trial, both participants and researchers know exactly which treatment each person is getting. There's no disguise involved.
Why Blinding Matters
Blinding exists to control for expectation effects. If a participant knows they're getting the "real" or the more promising drug, that knowledge alone can shift how they report symptoms, how carefully they stick to the protocol, or even physiological responses tied to expectation, the well-documented placebo effect. Blinding the people assessing outcomes matters too, since a researcher who knows a participant's treatment assignment might unconsciously interpret ambiguous results more favorably for the drug they expect to work better. This is why placebo-controlled, double-blind trials are generally treated as the strongest standard of evidence for a drug's efficacy, a point covered in more detail in this site's guide to placebo-controlled trials.
Why Some Trials Are Open-Label Anyway
Blinding isn't always practical. Comparing two different injectable devices with different dosing schedules, needle types, or injection-site instructions, as in a head-to-head trial between two different GLP-1-class drugs, often makes a truly convincing disguise difficult or impossible to pull off without introducing its own distortions. Rather than force an awkward blind that might not really work, researchers sometimes run these comparisons open-label and rely on objective, hard-to-fake endpoints, like a number on a scale, to limit how much the lack of blinding can bias the result.
A Recent Example
Novo Nordisk's REDEFINE 4 trial, which compared its experimental drug CagriSema against Eli Lilly's tirzepatide and is covered in more detail elsewhere on this site, was run open-label. Both participants and researchers knew who was getting which drug. The trial's primary endpoint, body weight, is about as objective and hard to consciously distort as a clinical measure gets, which is one reason the missed non-inferiority result there is still considered meaningful evidence. But it's also why any more subjective secondary outcomes from the same trial, like self-reported symptom severity or quality-of-life scores, deserve a slightly more skeptical read than they would in a blinded design.
How to Read Open-Label Results Without Overcorrecting
An open-label design is not a reason to dismiss a trial's findings outright. It's a reason to pay closer attention to which specific outcome is being reported: hard, objective endpoints (weight, lab values, hospitalization) hold up better under open-label conditions than soft, self-reported ones. It's also worth checking whether a result has been, or will be, replicated in an independently designed study, since a single open-label trial, however well-run, carries somewhat less weight on its own than a body of evidence including at least some blinded confirmation.
The Bottom Line
Trial design isn't a technicality reserved for statisticians. Knowing whether a peptide-drug result came from a blinded or an open-label trial is one of the fastest ways to calibrate how much confidence that specific number deserves, and it's a detail worth checking before treating any single headline trial result as the final word.